Company news
Gilead Sciences, Inc. (NASDAQ:GILD) news
Every Gilead Sciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those...
August 27, 2026
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
August 26, 2026
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
August 24, 2026
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
August 4, 2026
Gilead Sciences : Statement on California Supreme Court Decision in TDF Litigation
August 3, 2026
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
July 24, 2026
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HI...
July 21, 2026
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
June 24, 2026
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for...
June 23, 2026
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Preven...
June 15, 2026
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
June 12, 2026
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
June 11, 2026
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Tr...
June 8, 2026
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
June 5, 2026
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
June 4, 2026
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary ...
June 2, 2026
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization ...
May 27, 2026
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis De...
May 22, 2026
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates fo...
May 22, 2026
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
May 21, 2026
Gilead Prices $3 Billion of Senior Unsecured Notes
May 14, 2026
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
May 13, 2026
National casting call for E. Lynn Harris Invisible Life: The Musical With Original Score by Ashford & Simpson Announced
May 11, 2026
Gilead Sciences Announces First Quarter Financial Results
May 7, 2026
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
May 1, 2026
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
April 29, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
April 28, 2026
AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities
April 27, 2026
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 22, 2026
Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions
April 21, 2026
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
April 17, 2026
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
April 14, 2026
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
April 9, 2026
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
April 9, 2026
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Onc...
April 7, 2026
Gilead Extends Tender Offer to Acquire Arcellx
April 1, 2026
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
March 31, 2026
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
March 23, 2026
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the D...
March 2, 2026
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretr...
February 25, 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
February 23, 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
February 23, 2026
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novar...
February 20, 2026
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
February 17, 2026
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
February 10, 2026
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
February 10, 2026
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
February 6, 2026